GLYCOMIMETICS INC
0.37%
50,912
1253689
38000Q201
Jun 19, 2025
Jun 20, 2025, 04:05 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Adage Capital Management, L.P. | Investment Adviser | 0.37% | 50,912 | 0 | 50,912 |
| Robert Atchinson | Individual | 0.37% | 50,912 | 0 | 50,912 |
| Phillip Gross | Individual | 0.37% | 50,912 | 0 | 50,912 |
Disclosure Items (2)
Ordinary Shares, par value $0.001 per share
GLYCOMIMETICS INC
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each of the Reporting Persons. The percentages used in this Schedule 13D are calculated based upon 13,892,562 Ordinary Shares outstanding as of June 13, 2025 after giving effect to a 1-for-100 reverse stock split that was effected on June 13, 2025, the Merger and a redomestication that was effected on June 16, 2025, as disclosed in the Issuer's Current Report on Form 8-K, filed with the SEC on June 18, 2025.
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. The number of Ordinary Shares in this Schedule 13D give effect to the reverse stock split of 1-for-100 effected on June 13, 2025.
The Reporting Persons did not enter into any transactions in the Ordinary Shares during the past sixty days.
ACP has the right to receive, and the power to direct the receipt of dividends from, and the proceeds from the sale of, the Ordinary Shares.
June 13, 2025.